NCT04486976 is a NA clinical trial of Cornea/Anterior Segment OCT CASIA2 in Glaucoma, sponsored by Tomey Corporation.

Who is sponsoring NCT04486976?

NCT04486976 is sponsored by Tomey Corporation.

What drugs are being tested in NCT04486976?

Interventions in NCT04486976: Cornea/Anterior Segment OCT CASIA2, Optovue RTVue XR Avanti.

What condition does NCT04486976 study?

NCT04486976 studies Glaucoma, Cataract.

Is NCT04486976 still recruiting?

NCT04486976 is currently completed. Last updated 30 August 2021.

Last reviewed 2021-08-30 · How we verify

NCT04486976

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparative Study of the Cornea/Anterior Segment OCT CASIA2 and the RTVue XR OCT Avanti With AngioVue Software

Completed NA Last updated 30 August 2021

What this trial tests

NA trial testing Cornea/Anterior Segment OCT CASIA2 in Glaucoma in 134 participants. Completed in 5 March 2021.

Timeline

27 June 2020

Primary endpoint
5 March 2021

5 March 2021

Quick facts

Lead sponsor	Tomey Corporation
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	diagnostic
Enrollment	134
Start date	27 June 2020
Primary completion	5 March 2021
Estimated completion	5 March 2021
Sites	1 location across United States

Drugs / interventions tested

Cornea/Anterior Segment OCT CASIA2
Optovue RTVue XR Avanti

Conditions studied

Glaucoma — all drugs for Glaucoma →
Cataract — all drugs for Cataract →

Sponsor

Tomey Corporation

Who can join

22 and older, any sex, with Glaucoma or Cataract. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective comparative, randomized, single center study to gather agreement and precision data in all subjects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Glaucoma

Currently open trials in the same condition.

NCT07455786 — Modified Trabeculectomy After Failure of Combined Phaco With GATT · NA · recruiting
NCT07298356 — Automated Applanation Tonometry - Updated · NA · recruiting
NCT07217678 — Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use · Phase 4 · recruiting
NCT07145073 — Repetitive Transcranial Alternating Current Stimulation (rtACS) for the Treatment of Optic Neuropathies · NA · recruiting
NCT07209410 — Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanopro · Phase 4 · recruiting

Other Tomey Corporation trials

Trials by the same sponsor.

NCT06065072 — Comparative Study of the Tomey OA-2000, Tomey CASIA2, and the LenStar LS900 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04486976 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tomey Corporation
Last refreshed: 30 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04486976.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing